iBio (IBIO) Stock Is The Biggest Play In COVID-19 Vaccines

iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) is making a run for the top in the market this morning, following up on the strong gains that we saw yesterday. However, if you’re looking for press releases or SEC filings, it’s time to hang it up, there are none. Nonetheless, there’s good reason for the recent excitement surrounding the stock. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Here’s Why Investors Are Excited About IBIO Stock

iBio is a company that has been in the race to develop a COVID-19 vaccine since the race began. Early on, the company announced that it was working with a Chinese company called CC-Pharming to develop a viable vaccine for the virus.

Since its original announcement, the company has made some serious strides. First and foremost, IBIO announced that it is working on a second COVID-19 vaccine program. Of course, having more irons in the fire creates a better opportunity to create something of value.

Most recently however, IBM announced that it is making its IBM Clinical Development solution available to IBIO absolutely free for 18 months. This should help the company with the relatively speedy development of its vaccine candidates, ultimately giving the company yet another competitive advantage.

What Are IBIO’s Competitive Advantages?

The fact of the matter is that iBio has several competitive advantages in the race to produce and market a vaccine. Some of the most important include:

  • Partnership With CC-Pharming – First and foremost, IBIO has a partnership with CC-Pharming. Prior to the COVID-19 pandemic, CC-Pharming developed a viable vaccine for SARS, a sister virus to the virus that causes COVID-19. Having this kind of experience in the team makes a big difference in the development of a vaccine.
  • Multiple Irons In The Fire – The company isn’t only working on a single vaccine candidate. Instead, IBIO has announced that it has two clinical development programs surrounding vaccination against COVID-19. As mentioned above, the more irons in the fire, the more opportunity for something valuable to be the result.
  • FastPharming Facility – Several years ago, the United States government commissioned the development of a FastPharming Facility. The Facility would have the ability to produce vaccines and biologicial agents at lightning-like speeds in an effort to fight back pandemics. Years later, here we are with IBIO owning the only FastPharming Facility in the world. This gives the company a massive competitive advantage when it comes to the manufacturing of mass quantities of vaccine.
  • IBM Clinical Development – Finally, the fact that IBM Clinical Development was made available to the company for free for 18 months not only serves as validation for the company’s work to date, but provides iBio with yet another competitive advantage.

The Bottom Line

The bottom line here is simple. IBIO has multiple vaccines under development, a partner that has developed vaccines for a sister virus in the past, the FastPharming Facility to provide fast manufacturing once approved and the IBM Clinical Development Suite to improve the quality of data and speed up time to approval. All in all, IBIO is hard to ignore if you’re interested in investing in coronavirus vaccine development.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.